Nippon Shinyaku (4516 JP): Viltepso Has Strong Muscle Power; New Seizure Drug Launch in Japan

Strong performance of DMD drug Viltepso in US market and reviving functional food business have enabled the company to raise FY23 guidance. Late-stage pipeline brightens sustainable growth prospect.

SUMMARY

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

• Unlimited Research Summaries
• Personalised Alerts
• Custom Watchlists
• Company Data & News
• Events & Webinars

Trusted by:

SMARTKARMA PREVIEW PASS

Sign Up with LinkedIn

or

First NameLast nameEmail

Sign Up with EmailBy signing up, you agree to our
Terms of Use and Privacy Policy.

Trusted by:

Already have an account? Sign In Now

---